Synthetic Blood International Receives Patent for Respiritory Treatment

Synthetic Blood International Inc. recently announced that a new patent for Fluorovent, its liquid ventilation product, has been issued in Australia.

The patent, titled ``Perfluorocarbons for Assisting Normal Breathing in Mammals Having Lung Disorders,'' covers the use of Fluorovent in treating respiratory disorders in adults and children. The patent also protects the use of two specific perfluorocarbons with differing characteristics to control pulmonary dwell time.

In addition to Fluorovent, Synthetic Blood is developing Oxycyte, a perfluorocarbon blood substitute emulsion, and an implanted biosensor for continuous monitoring of blood glucose levels in diabetics.

For more information: Joan Mahan, Synthetic Blood International Inc. Tel: 800-809-6054.